Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy

Article Cardiac & Cardiovascular Systems

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Kausik K. Ray et al.

Summary: Exploratory findings from the ORION trials suggest that treatment with inclisiran is associated with reductions in major cardiovascular events, providing potential cardiovascular benefits.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Kausik K. Ray et al.

Summary: This study aimed to assess the long-term effect of inclisiran on patients with high cardiovascular risk and elevated LDL cholesterol. The results showed that twice-yearly treatment with inclisiran resulted in sustained reductions in LDL cholesterol and was well tolerated over 4 years.

LANCET DIABETES & ENDOCRINOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia-The Future Is Here

Melody Hermel et al.

Summary: This article provides an update on the use of monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. It reviews the cutting-edge pharmaceuticals targeting LDL cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3. The available and upcoming biotechnological lipid therapies are discussed for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.

PHARMACEUTICS (2023)

添加到收藏夹

Article

New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)

Kyung An Kim et al.

Journal of Lipid and Atherosclerosis (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review

Priyanga Ranasinghe et al.

Summary: Post-transcriptional gene silencing can be achieved through siRNA therapy, which uses synthetic short double-stranded RNA molecules to specifically target and degrade mRNA transcripts. This technology offers advantages such as broad targeting capabilities and long-lasting effects. However, challenges in terms of pharmacokinetics and pharmacodynamics have been addressed through chemical modification and delivery systems. Several siRNA therapies have been approved for clinical use, but further advancements are needed to target organs beyond the liver and reach special sites.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews

Jiayi Li et al.

Summary: This study comprehensively evaluated the effectiveness and safety of Inclisiran in treating hyperlipidemia through systematic reviews. The results showed that 300mg Inclisiran with 2 injections a year had the best therapeutic effect, significantly reducing low-density lipoprotein cholesterol and total cholesterol, and increasing high-density lipoprotein cholesterol levels. Inclisiran had a favorable safety profile, with no significant difference in adverse reaction incidence compared to a placebo.

MEDICINE (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

Yajnavalka Banerjee et al.

Summary: Inclisiran is a novel therapy that silences PCSK9 synthesis through RNA interference, effectively reducing LDL-C levels and lowering the risk for cardiovascular events. Clinical trials have shown its safety and efficacy, with injection-site reactions being more common than in the placebo group. Further studies are needed to ensure its specificity in targeting PCSK9 without affecting other physiological mRNAs.

EXPERT OPINION ON DRUG SAFETY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis

Adam Kramer et al.

Summary: This study aimed to assess the prevalence and age-of-onset of major adverse cardiovascular events (MACE) among patients with Homozygous Familial Hypercholesterolaemia (HoFH). The findings showed that atherosclerotic cardiovascular disease is common among HoFH patients and occurs at a young age. The age-of-onset of myocardial infarction was delayed by more than a decade from pre-1990 to post-1990, reflecting substantial progress in the management of this rare but severe disorder.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Existing and emerging strategies to lower Lipoprotein(a)

Gregory G. Schwartz et al.

Summary: Elevated levels of lipoprotein(a) are linked to higher cardiovascular risk, and current therapeutic options for reducing lipoprotein(a) levels are limited. PCSK9 inhibitors and lipoprotein apheresis are the only effective methods to lower lipoprotein(a) and reduce cardiovascular risk.

ATHEROSCLEROSIS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction

Kimberly W. Smith et al.

Summary: Inclisiran, a novel small interfering RNA molecule, increases the expression of low-density lipoprotein surface receptors on hepatocytes, leading to a reduction in low-density lipoprotein. It is indicated for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease. Compared to other options, Inclisiran has a convenient dosing protocol and a favorable safety profile.

JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Review Peripheral Vascular Disease

Inclisiran: How Widely and When Should We Use It?

Angela Pirillo et al.

Summary: In this review, the efficacy and safety of inclisiran, a siRNA targeting PCSK9, in reducing LDL-C levels is discussed. Randomized clinical trials have shown that inclisiran provides durable reductions of PCSK9 and LDL-C levels, with a dosing schedule of once every 6 months. These effects are consistent in different categories of patients, and the drug's safety profile is favorable.

CURRENT ATHEROSCLEROSIS REPORTS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Small interfering ribonucleic acid for cholesterol lowering - Inclisiran

Daniel Soffer et al.

Summary: Despite the development of new therapies, the trend of reductions in cardiovascular disease (CVD) mortality has reversed. Lowering low-density lipoprotein cholesterol (LDL-C) is important for preventing and managing atherosclerotic CVD (ASCVD), but many patients with established ASCVD fail to achieve guideline-recommended LDL-C targets.

JOURNAL OF CLINICAL LIPIDOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Byeong-Keuk Kim et al.

Summary: Through a randomized trial, it was found that the combination therapy of moderate-intensity statin and ezetimibe is as effective as high-intensity statin monotherapy in reducing cardiovascular events and maintaining stable LDL cholesterol concentrations, with better drug tolerance.

LANCET (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Michelle L. O'Donoghue et al.

Summary: Long-term use of evolocumab to lower LDL-C levels is associated with low rates of adverse events, which do not exceed those in the placebo group. Over time, the use of evolocumab also leads to further reduction in cardiovascular events.

CIRCULATION (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection

Natalie Arnold et al.

Summary: This review critically summarizes the emerging cholesterol-lowering therapy targeting PCSK9, with a focus on the use of anti-PCSK9 monoclonal antibodies (mAbs) and inclisiran. Although both drug classes show similar efficacy in reducing LDL-C levels, the long-term safety and CV outcomes of inclisiran are still unknown.

CURRENT CARDIOLOGY REPORTS (2022)

添加到收藏夹

Review Cell Biology

PCSK9 Inhibition: From Current Advances to Evolving Future

Chunping Liu et al.

Summary: This article summarizes the application, preclinical studies, safety, mechanism of action, and latest research progress of PCSK9 inhibitors. It aims to provide ideas for drug research and development, as well as expand the application of PCSK9 inhibitors in other diseases.

CELLS (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials

Wolfgang Koenig et al.

Summary: This study analyzed the lipid-lowering efficacy and safety of inclisiran versus placebo in patients with and without polyvascular disease (PVD). The results showed that twice-yearly inclisiran dosing effectively reduced LDL-C levels and was well tolerated in patients, irrespective of PVD status.

CARDIOVASCULAR DRUGS AND THERAPY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

A Comprehensive Review of PCSK9 Inhibitors

Caroline Coppinger et al.

Summary: Cardiovascular disease is a leading cause of death globally, and high levels of LDL-C are a major risk factor. PCSK9 inhibitors have been found to significantly reduce LDL-C levels and lower the occurrence of major adverse cardiovascular events in high-risk patients. They can be used in populations who are intolerant to statins or do not achieve their treatment goals.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels * , **

Vanessa Bianconi et al.

Summary: Familial hypercholesterolemia (FH) is a common genetic disorder characterized by elevated LDL-C levels due to defective clearance of LDL particles, leading to increased risk of premature cardiovascular disease. Besides LDL-C, other CVD risk factors may also contribute to the overall CVD risk burden in FH patients.

TRENDS IN CARDIOVASCULAR MEDICINE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

The growth of siRNA-based therapeutics: Updated clinical studies

M. May Zhang et al.

Summary: After more than twenty years since the discovery of the natural gene-silencing mechanism of RNA interference, siRNA-based therapeutics have entered the pharmaceutical market with three approved drugs and many others in advanced stages of development. The majority of late-stage candidates are targeted towards rare diseases or patients who have not responded to current treatments, while some have potential for a wider patient population. This review provides an overview of siRNA mechanisms, barriers to delivery, and profiles of approved drugs and candidates in Phase 3 clinical trials.

BIOCHEMICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Inclisiran: First Approval

Yvette N. Lamb

Summary: Inclisiran is a first-in-class cholesterol-lowering drug administered through subcutaneous injection, approved for use in patients with primary hypercholesterolaemia or mixed dyslipidaemia.

DRUGS (2021)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Inclisiran A Game Changer in a Changing Game?

Vijay Nambi et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities

Harry E. Walker et al.

Summary: Elevated LDL-C is causally associated with atherosclerotic cardiovascular disease, and advancements in reducing LDL-C through statins and PCSK9 drugs have been made. However, approaches targeting PCSK9 need further improvement, and CRISPR gene-editing shows promise as a tool for lifelong LDL-C reduction.

METABOLITES (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications

Xiao-dan Xia et al.

Summary: PCSK9 plays a vital role in promoting cardiovascular disease and cancer by degrading LDLR and affecting tumor growth. Inhibition of PCSK9 can reduce the risk of cardiovascular disease and cancer.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

添加到收藏夹

Article Cell Biology

An oral antisense oligonucleotide for PCSK9 inhibition

Peter Gennemark et al.

Summary: In this study, a chemically modified PCSK9 antisense oligonucleotide (ASO) with potential for oral delivery was developed and shown to effectively reduce LDL cholesterol levels. Animal experiments demonstrated liver targeting and significant reductions in PCSK9 and LDL cholesterol levels after oral administration.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Hydrophilic or Lipophilic Statins?

Elisenda Climent et al.

Summary: Statins can be classified as hydrophilic or lipophilic, with different solubility profiles potentially impacting cardiovascular outcomes and adverse effects. The superiority of one type of statin over another in terms of solubility remains uncertain, with conflicting results observed in previous studies on cardiovascular and heart failure outcomes.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

PCSK9 vaccine: so near, yet so far!

Amirhossein Sahebkar et al.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

siRNA: Mechanism of action, challenges, and therapeutic approaches

Walhan Alshaer et al.

Summary: siRNA functions in gene silencing and targets disease-related genes, yet it faces issues such as low cellular uptake and susceptibility to degradation, requiring a carrier for protection and delivery.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9

Carlota Oleaga et al.

Summary: Our study confirms that PCSK9_55 is predominantly formed extracellularly with a shorter half-life, while a small intracellular pool of PCSK9_55 remains non-secreted. Intracellularly retained PCSK9_55 exhibits reduced efficiency in inducing LDLR degradation compared to PCSK9_62.

JOURNAL OF LIPID RESEARCH (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

Francois Mach et al.

EUROPEAN HEART JOURNAL (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Inclisiran-New hope in the management of lipid disorders?

Krzysztof Dyrbus et al.

JOURNAL OF CLINICAL LIPIDOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

R. Scott Wright et al.

MAYO CLINIC PROCEEDINGS (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran

Laurien E. Zijlstra et al.

MAYO CLINIC PROCEEDINGS (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction

Akihiro Nakamura et al.

JOURNAL OF CARDIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Frederick J. Raal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Physiology

Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9

Klaus-Dieter Schlueter et al.

FRONTIERS IN PHYSIOLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data

Larysa Strilchuck et al.

EXPERT OPINION ON DRUG SAFETY (2019)

添加到收藏夹

Meeting Abstract Cardiac & Cardiovascular Systems

SAFETY, TOLERABILITY AND LDL-C REDUCTION WITH A NOVEL ANTI-PCSK9 RECOMBINANT FUSION PROTEIN (LIB003): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY

E. Stein et al.

ATHEROSCLEROSIS (2019)

添加到收藏夹

Review Endocrinology & Metabolism

Endocrine diseases as causes of secondary hyperlipidaemia

Lukasz Buldak et al.

ENDOKRYNOLOGIA POLSKA (2019)

添加到收藏夹

Review Pathology

PCSK9: from biology to clinical applications

Valentin Blanchard et al.

PATHOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis

Lukas Schwingshackl et al.

JOURNAL OF LIPID RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts

R. Estruch et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease

Asier Benito-Vicente et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

添加到收藏夹

Review Endocrinology & Metabolism

Inhibiting PCSK9-biology beyond LDL control

Robert M. Stoekenbroek et al.

NATURE REVIEWS ENDOCRINOLOGY (2018)

添加到收藏夹

Article Food Science & Technology

Scientific opinion on the safety of monacolins in red yeast rice

Maged Younes et al.

EFSA JOURNAL (2018)

添加到收藏夹

Review Chemistry, Medicinal

Coumarin and Derivates as Lipid Lowering Agents

Silvia Tejada et al.

CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Genome editing in cardiovascular diseases

Alanna Strong et al.

NATURE REVIEWS CARDIOLOGY (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Ezetimibe: an update on its clinical usefulness in specific patient groups

Daniel Hammersley et al.

THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia

Yu Kataoka et al.

JOURNAL OF CLINICAL LIPIDOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Marc S. Sabatine et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Editorial Material Medicine, General & Internal

Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs

Anastasia Khvorova

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Letter Medicine, General & Internal

Antidrug Antibodies in Patients Treated with Alirocumab

Eli M. Roth et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Food supplements with red yeast rice: More regulations are needed

Guy G. De Backer

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Genome Editing for the Study of Cardiovascular Diseases

Alexandra C. Chadwick et al.

CURRENT CARDIOLOGY REPORTS (2017)

添加到收藏夹

Article Medicine, General & Internal

Statins: pros and cons

Iago Pinal-Fernandez et al.

MEDICINA CLINICA (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Hypercholesterolemia: The role of PCSK9

Quantil M. Melendez et al.

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Safety of antisense oligonucleotide and siRNA-based therapeutics

Xuan Chi et al.

DRUG DISCOVERY TODAY (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

PCSK9 inhibitors: A new era of lipid lowering therapy

Rahul Chaudhary et al.

WORLD JOURNAL OF CARDIOLOGY (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis

Bjorn W. Karlson et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2016)

添加到收藏夹

Article Hematology

CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report

Xiao Wang et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)

添加到收藏夹

Article Peripheral Vascular Disease

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration

Antonio J. Vallejo-Vaz et al.

ATHEROSCLEROSIS SUPPLEMENTS (2016)

添加到收藏夹

Review Biology

CRISPR-Cas: biology, mechanisms and relevance

Frank Hille et al.

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2016)

添加到收藏夹

Article Peripheral Vascular Disease

Familial Hypercholesterolemia-Epidemiology, Diagnosis, and Screening

Siddharth Singh et al.

CURRENT ATHEROSCLEROSIS REPORTS (2015)

添加到收藏夹

Article Medicine, General & Internal

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal et al.

LANCET (2015)

添加到收藏夹

Article Multidisciplinary Sciences

In vivo genome editing using Staphylococcus aureus Cas9

F. Ann Ran et al.

NATURE (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing

Qiurong Ding et al.

CIRCULATION RESEARCH (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Erik Stroes et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

Thazha P. Prakash et al.

NUCLEIC ACIDS RESEARCH (2014)

添加到收藏夹

Article Primary Health Care

Hyperlipidemia as a Risk Factor for Cardiovascular Disease

Robert H. Nelson

PRIMARY CARE (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels

Michael T. Lipari et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2012)

添加到收藏夹

Review Peripheral Vascular Disease

Ezetimibe therapy: mechanism of action and clinical update

Binh An P. Phan et al.

VASCULAR HEALTH AND RISK MANAGEMENT (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias

Zeljko Reiner et al.

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)

添加到收藏夹

Review Biochemistry & Molecular Biology

A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: Results of a meta-analysis of randomized, placebo-controlled trials

Kathy Musa-Veloso et al.

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

ESC/EAS Guidelines for the management of dyslipidaemias

Zeljko Reiner et al.

EUROPEAN HEART JOURNAL (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Lipoprotein(a) as a cardiovascular risk factor: current status

Borge G. Nordestgaard et al.

EUROPEAN HEART JOURNAL (2010)

添加到收藏夹

Review Multidisciplinary Sciences

A historical perspective on the discovery of statins

Akira Endo

PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2010)

添加到收藏夹

Article Medicine, General & Internal

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

A. Pandor et al.

JOURNAL OF INTERNAL MEDICINE (2009)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study

J. Hippisley-Cox et al.

HEART (2008)

添加到收藏夹

Review Medicine, General & Internal

Ezetimibe-associated adverse effects: what the clinician needs to know

M. Florentin et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)

添加到收藏夹

Article Biochemistry & Molecular Biology

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications

Suzanne Benjannet et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study

JA Cooper et al.

ATHEROSCLEROSIS (2005)

添加到收藏夹

Article Multidisciplinary Sciences

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment

KN Maxwell et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia

MH Davidson et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2004)

添加到收藏夹

Review Pharmacology & Pharmacy

Simvastatin: a review

TR Pedersen et al.

EXPERT OPINION ON PHARMACOTHERAPY (2004)

添加到收藏夹

Article Genetics & Heredity

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

M Abifadel et al.

NATURE GENETICS (2003)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and safety of Ezetimibe coadministered with Lovastatin in primary hypercholesterolemia

B Kerzner et al.

AMERICAN JOURNAL OF CARDIOLOGY (2003)

添加到收藏夹

Article Pharmacology & Pharmacy

Lovastatin extended release - A review of its use in the management of hypercholesterolaemia

MP Curran et al.

DRUGS (2003)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

C Gagné et al.

CIRCULATION (2002)

添加到收藏夹

Article Medicine, General & Internal

Validation of the Framingham Coronary Heart Disease prediction scores - Results of a multiple ethnic groups investigation

RB D'Agostino et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)

添加到收藏夹

Article Multidisciplinary Sciences

An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis

LW Chiang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

添加到收藏夹

Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy

相关参考文献

导出引文

分享论文